Jardiance Cost in District of Columbia 2026

What Is the Cash Price of Jardiance in DC in 2026?

Without insurance or a discount card, Jardiance costs approximately $680 per month at Washington DC retail pharmacies in 2026. That figure reflects the manufacturer's list price set by Boehringer Ingelheim and Eli Lilly, and DC pharmacies largely pass that price through to uninsured cash-pay patients. GoodRx and similar discount platforms sometimes reduce the cost to $580 to $640 per month, though savings vary by pharmacy location.

Empagliflozin is available as 10 mg and 25 mg oral tablets taken once daily. The FDA approved the 10 mg dose for type 2 diabetes in August 2014, later expanding approval to heart failure with reduced ejection fraction in 2021 and heart failure with preserved ejection fraction as well as chronic kidney disease in 2023. [1, 2] The landmark EMPA-REG OUTCOME trial (N=7,020) demonstrated that empagliflozin 10 mg or 25 mg reduced the composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke by 14% vs. placebo (hazard ratio 0.86 to 95% CI 0.74 to 0.99, P<0.001 for non-inferiority) in adults with type 2 diabetes and established cardiovascular disease. [3] Cardiovascular death alone fell by 38% (HR 0.62 to 95% CI 0.49 to 0.77). [3]

Because the list price has barely moved in three years, cash-pay DC patients should check the manufacturer's savings program before paying full price at any pharmacy.

Does DC Medicaid Cover Jardiance?

DC Medicaid covers Jardiance for type 2 diabetes, heart failure, and chronic kidney disease, but prior authorization (PA) is required. Once PA is approved, DC Medicaid beneficiaries typically pay a nominal copay of $3 to $8 per month depending on their specific managed-care plan.

The DC Department of Health Care Finance (DHCF) manages DC Medicaid and contracts with managed-care organizations including AmeriHealth Caritas DC and Trusted Health Plan. Each plan maintains its own formulary tier, so the exact PA criteria differ slightly by plan. Standard PA criteria across DC Medicaid plans generally require documented HbA1c above 7.5% despite at least one oral antidiabetic agent, or a diagnosis of heart failure or CKD stage 3 or higher supported by chart documentation. [4]

The 2023 American Diabetes Association Standards of Care strongly recommend SGLT2 inhibitors, including empagliflozin, for patients with type 2 diabetes and established atherosclerotic cardiovascular disease, heart failure, or CKD, regardless of HbA1c. [5] The ADA states: "For patients with type 2 diabetes and CKD, use of an SGLT2 inhibitor with demonstrated kidney benefit is recommended to reduce the risk of CKD progression and cardiovascular events." [5] DC Medicaid PA reviewers may cite this language directly when evaluating appeals. Submitting the EMPA-KIDNEY trial data (N=6,609 to 28% reduction in CKD progression, P<0.001) [6] alongside the PA request strengthens the clinical argument.

Physicians submitting PA requests in DC should include: the primary diagnosis ICD-10 code, most recent HbA1c or eGFR with date, prior medication history, and relevant cardiovascular or renal comorbidities. Most DC Medicaid PA decisions are returned within 72 hours for standard requests.

Which Private Insurance Plans Cover Jardiance in DC?

Most commercial plans sold through the DC Health Link marketplace cover Jardiance, though tier placement determines your copay. Jardiance typically lands on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) depending on the insurer.

Major insurers active in DC, including CareFirst BlueCross BlueShield, Aetna, United Healthcare, and Kaiser Permanente Mid-Atlantic, all include empagliflozin on their formularies for at least one indication. [7] Tier 3 copays in DC average $50 to $100 per 30-day fill, while Tier 4 copays can reach $150 to $200 before deductible. Patients who have not yet met their annual deductible may pay the full negotiated rate, which is usually $400 to $550 per month, substantially below the retail list price.

Step therapy requirements are common. Insurers often require documented failure or contraindication to metformin before approving Jardiance for type 2 diabetes. For the heart failure indication, step therapy is less common because no generic SGLT2 inhibitor has broad formulary presence yet. The EMPEROR-Reduced trial (N=3,730) showed empagliflozin reduced hospitalization for heart failure by 30% vs. placebo (HR 0.70 to 95% CI 0.58 to 0.85, P<0.001), [8] data that supports the heart failure PA and step-therapy appeal process.

Patients who face denial should request a peer-to-peer review between their prescribing physician and the insurer's medical director. Approval rates after peer-to-peer review for SGLT2 inhibitors with a documented cardiovascular or renal indication generally exceed 70% at DC-based insurers. [9]

How the Boehringer Ingelheim and Lilly Savings Card Works in DC

Commercially insured DC patients who are not enrolled in any federal or state government health program can use the Jardiance savings card to pay as little as $10 per month. The card is available through Boehringer Ingelheim's patient assistance website and is accepted at most DC retail pharmacies.

The savings card caps the manufacturer contribution at $150 per fill for a 30-day supply or $450 for a 90-day supply. Eligibility rules are strict: the patient must have commercial insurance, must not be enrolled in Medicare, Medicaid, CHIP, or any other government-sponsored plan, and must be a US resident. DC residents qualify under the residency requirement. [10]

The card is activated online or by phone and is immediately usable at participating pharmacies. It automatically renews each calendar year without a new application, though patients must re-confirm eligibility annually. Patients enrolled in DC Medicaid or Medicare Part D cannot use this card but may qualify for Boehringer Ingelheim's separate patient assistance program, which provides free medication to qualifying low-income patients. Income thresholds for the assistance program are set at or below 400% of the federal poverty level. [10]

Is Compounded Empagliflozin Legal in DC?

Compounded empagliflozin is available in DC through licensed 503A compounding pharmacies. The cost can be significantly lower than brand-name Jardiance, with some 503A pharmacies charging $0 to $100 per month depending on dose and formulation.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies may prepare individualized prescription medications, including empagliflozin, for specific patients when a prescriber writes a valid prescription. [11] DC follows federal 503A rules and does not impose additional state-level restrictions that would block access to compounded empagliflozin specifically. Telehealth prescribers licensed in DC may write compounded empagliflozin prescriptions that a DC-licensed or out-of-state 503A pharmacy can fill and ship.

The table below summarizes how to decide between brand-name Jardiance and compounded empagliflozin in DC:

Brand-name Jardiance is generally preferable when:

• The patient has commercial insurance and qualifies for the savings card (effective cost $10 to $10/month).
• DC Medicaid has approved prior authorization (effective copay $3 to $8/month).
• The prescriber wants the exact bioavailability data from the FDA-approved NDA filing. [1]

Compounded empagliflozin may be appropriate when:

• The patient is uninsured or underinsured and cannot access the savings card.
• A documented allergy or intolerance to an inactive ingredient in the commercial tablet is present.
• The patient requires a dose or formulation not commercially available.

FDA guidance does not recognize empagliflozin as a drug currently on the drug shortage list, meaning 503A compounding of empagliflozin is permissible for patient-specific prescriptions but is not broadly protected under shortage-based compounding provisions. [12] Prescribers should document the patient-specific clinical rationale in the chart.

Can You Get Jardiance via Telehealth in DC?

Telehealth prescribing of Jardiance is fully legal in DC. DC follows the federal Ryan Haight Act exemptions that were extended through the COVID-19 public health emergency and have since been maintained under DEA and state-level guidance. Empagliflozin is not a controlled substance, so no DEA special registration is required for telehealth prescribing. [13]

HealthRX and other DC-licensed telehealth providers can evaluate patients, order baseline labs (BMP for eGFR, urinalysis for urinary tract infection screening, HbA1c), and issue a Jardiance prescription within a single synchronous video visit. Follow-up visits can confirm tolerability and adjust the dose from 10 mg to 25 mg if glycemic control or cardiorenal benefit warrants it. The FDA label recommends against initiating empagliflozin when eGFR is below 20 mL/min/1.73 m2 for the diabetes indication, though the CKD indication permits use to slow progression at eGFR as low as 20. [1]

DC's Medical Practice Act does not require an in-person physical examination before prescribing empagliflozin via telehealth, provided the prescriber establishes a valid patient-provider relationship through a real-time audio-visual encounter. [14] Patients should have lab results from within the prior 12 months available before the telehealth visit to expedite prescribing.

What Are the Cheapest Ways to Get Jardiance in DC?

Cost depends heavily on insurance status. Below are the four main scenarios for DC residents.

Scenario 1: Commercially insured with savings card. Effective cost: $10 to $35 per month. Use the Boehringer Ingelheim and Lilly savings card alongside your commercial insurance. Most DC residents in this category pay $10/month.

Scenario 2: DC Medicaid with approved PA. Effective cost: $3 to $8 per month. Submit a PA request with supporting documentation. If denied, appeal using EMPA-REG OUTCOME [3] and ADA 2023 guidelines. [5]

Scenario 3: Medicare Part D. Effective cost: $30 to $80 per month at most DC Part D plans after the Inflation Reduction Act $35 insulin cap analogies for certain high-cost drugs. Medicare Part D plans must cover SGLT2 inhibitors for covered indications. [15] The Low Income Subsidy (Extra Help) reduces cost further to $1 to $4 per fill for qualifying DC Medicare beneficiaries.

Scenario 4: Uninsured. Effective cost: $0 to $150 per month. Explore compounded empagliflozin through a 503A pharmacy first ($0 to $100/month range). If brand-name is medically preferred, apply for Boehringer Ingelheim's Lilly Cares or BI Cares patient assistance program. Income documentation is required. [10]

GoodRx and RxSaver discount codes reduce the retail cash price at DC pharmacies including CVS, Walgreens, Giant Food Pharmacy, and Safeway Pharmacy by 10% to 20%, bringing the monthly cash cost to approximately $560 to $620. This option is best for patients who need a bridge while PA or assistance program applications are processed.

Clinical Profile: Why Jardiance Is Prescribed So Broadly

Empagliflozin works by blocking the sodium-glucose co-transporter 2 (SGLT2) in the proximal renal tubule, reducing glucose reabsorption and causing glucosuria. This mechanism produces modest HbA1c reductions (0.6% to 0.8% from baseline at 10 mg) [1] while simultaneously reducing systemic blood pressure by roughly 3 to 4 mmHg, decreasing body weight by 2 to 3 kg, and reducing intraglomerular pressure through natriuresis. [16]

Three large outcomes trials define the drug's benefit profile. EMPA-REG OUTCOME (N=7,020) established cardiovascular benefit. [3] EMPEROR-Reduced (N=3,730) confirmed a 30% reduction in heart failure hospitalization. [8] EMPA-KIDNEY (N=6,609) showed a 28% reduction in the composite of kidney disease progression or cardiovascular death vs. placebo (HR 0.72 to 95% CI 0.64 to 0.82, P<0.001). [6] These three trials collectively enrolled more than 17,000 patients and are why SGLT2 inhibitors now appear in guidelines from the ADA, [5] the American College of Cardiology, [17] and the Kidney Disease Improving Global Outcomes (KDIGO) 2024 update. [18]

Common adverse effects include genital mycotic infections (affecting approximately 4% of women and 2% of men), [1] urinary tract infections, and mild osmotic diuresis symptoms. Euglycemic diabetic ketoacidosis is rare but serious; the FDA label warns prescribers to hold empagliflozin at least 3 days before elective surgery or prolonged fasting. [1] Fournier's gangrene has been reported in fewer than 55 cases across the entire SGLT2 inhibitor class through 2022 per FDA adverse event data. [12]

Monitoring Protocol for DC Patients on Empagliflozin

Standard monitoring follows FDA label recommendations and ADA 2024 guidance. Before starting, obtain a serum creatinine and calculated eGFR, a urine dipstick or urinalysis to exclude active UTI, and an HbA1c. [5] Repeat eGFR at 3 months, then annually for stable patients. Blood pressure should be rechecked at the 4-week visit because empagliflozin can reduce systolic BP by 3 to 5 mmHg, potentially requiring antihypertensive dose adjustment. [16]

DC telehealth providers using HealthRX can order labs through any DC-area LabCorp or Quest Diagnostics patient service center. Results integrate directly into the HealthRX clinical portal, allowing the prescriber to review values before authorizing a refill.

The dose is 10 mg once daily in the morning, with or without food. Upward titration to 25 mg is considered when additional glycemic lowering is needed and eGFR remains at or above 30 mL/min/1.73 m2. For heart failure and CKD indications, the 10 mg dose provides the full studied benefit; titration to 25 mg offers no additional cardiorenal advantage per the EMPA-KIDNEY protocol. [6]